

## **Anastasios Ioannidis, BSc, MD, PhD**

Associate Professor of Microbiology

Department of Nursing, Faculty of Health Sciences

University of Peloponnese, Tripoli, Greece

Mail: [tasobi@gmail.com](mailto:tasobi@gmail.com), [tasobi@uop.gr](mailto:tasobi@uop.gr)

<https://www.ncbi.nlm.nih.gov/myncbi/1FIjaf0k-wGQA/bibliography/public/>

### **Education**

2007: MD in Medical School of Athens, National and Kapodistrian University of Athens.

2006: PhD in Microbiology, Medical School of Athens, National and Kapodistrian University of Athens.

1997: BSc in Biology, Department of Biology, National and Kapodistrian University of Athens.

### **Research interests**

Bacteriology with special emphasis on antimicrobial resistance mechanisms, therapeutic repurposing of non-antibiotics and the understanding of natural compounds antimicrobial identity, microbial biofilms, microbial virulence genetic association and gene expression studies, genetic epidemiology in humans, recombinant DNA technology and sero-epidemiology.

### **Research projects**

10/2009-09/2010: "Genetic Epidemiology of metabolic syndrome", (Greek Ministry of Health)

01/2005-06/2005 and 04/2006-12/2006: "PYTHAGORAS II: Development a database with genotypic and phenotypic characteristics of clinical isolates *Campylobacter jejuni* strains from Greece. " (EPEAEK II)

11/2002-07/2005: "IRAKLEITOS: Molecular epidemiology of *Campylobacter jejuni* strains from clinical isolates" (EPEAEK II)

### **Scientific Activity**

Anastasios Ioannidis has been Associate Professor in Microbiology works in the fields of genetic association and gene expression studies, recombinant DNA technology, microbial biofilms, microbial virulence and seroepidemiology at the Department of Nursing of the University of Peloponnese. His scientific activity includes 72 publications in peer reviewed international journals, with a citation index of 1988 citations in Google Scholar h-index 19 i10-index 38, 7 in Google Books, 95 participations with research work in national and international congresses and 23 presentations as a speaker at scientific meetings. He is reviewer in 8 peer reviewed scientific journals.

### **Selective Publications**

Magana M, Pushpanathan M, Santos AL, Leanse L, Fernandez M, Ioannidis A, et al. **The value of antimicrobial peptides in the age of resistance.** The Lancet Infectious diseases. 2020;20(9):e216-e30

Magana M, Sereti C, Ioannidis A, Mitchell C, Ball A, Magiorkinis E, Chatzipanagiotou S, Hamblin M, Hadjifrangiskou M, and Tegos G. **Options and limitations in bacterial**

**biofilm clinical investigation.** *Clinical Microbiology Reviews* 2018 Apr 4;31(3). pii: e00084-16. doi: 10.1128/CMR.00084-16

Angelopoulou M, Makarona E, Salapatas A, Misiakos K, Synolaki E, Ioannidis A, et al. **Directly immersible silicon photonic probes: Application to rapid SARS-CoV-2 serological testing.** *Biosensors & bioelectronics.* 2022;215:114570.

Ioannidis A, Chatzipanagiotou S, Vassilaki N, Giannakopoulos P, Hatzaki D, Magana M, Sachlas A, Mpekoulis G, Radiotis A, Tsakanikos M, Tzanakaki G, Lebessi E, Tsolia MN. **Biofilm-forming bacteria implicated in complex otitis media in children in the post-heptavalent pneumococcal conjugate vaccine (PCV7) era.** *Microorganisms*, 2111919 - Accepted for Publication 16.02.2023

Hamel M, Chatzipanagiotou S, Hadjadj L, Petinaki E, Papagianni S, Charalampaki N, et al. **Inactivation of mgrB gene regulator and resistance to colistin is becoming endemic in carbapenem-resistant Klebsiella pneumoniae in Greece: A nationwide study from 2014 to 2017.** *International journal of antimicrobial agents.* 2020;55(4):105930

Tsiakos K, Tsakiris A, Tsibris G, Voutsinas PM, Panagopoulos P, Kosmidou M, et al. **Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial.** *Infectious diseases and therapy.* 2021.

Falagas, M.E., et al., **Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.** *Int J Antimicrob Agents.* 2018 Aug;52(2):269-271. doi:10.1016/j.ijantimicag.2018.03.009

Ioannidis A, Papaioannou P, Magiorkinis E, Magana M, Ioannidou V, Tzanetou K, Burriel AR, Tsironi M, Chatzipanagiotou S. **Detecting the Diversity of Mycoplasma and Ureaplasma Endosymbionts Hosted by Trichomonas vaginalis Isolates.** *Front Microbiol.* 2017 Jun 28;8:1188. doi: 10.3389/fmicb.2017.01188

Rivas A.L, Leitner G., Jankowski M.D., Hoogesteijn A.L., Iandiorio M.D., Chatzipanagiotou S., Ioannidis A., Blum S.E., Piccinini R., Antoniadis A., Fazio J., Apidianakis Y., Fair J.M. and Van Regenmortel M.H.V., **Nature and consequences of biological reductionism for the immunological study of infectious diseases.** *Front Immunol.* 2017 May 31;8:612. doi: 10.3389/fimmu.2017.00612.

Tegou E, Magana M, Katsogridaki AE, Ioannidis A, Raptis V, Jordan S, Chatzipanagiotou S, Chatzandroulis S, Ornelas C, Tegos GP. **Terms of endearment: Bacteria meet graphene nanosurfaces.** *Biomaterials.* 2016 May;89:38-55.

Vasileios Kordinas, George Tsirpanlis, Chryssoula Nicolaou, Margarita Zoga, Anastasios Ioannidis, Vasiliki Ioannidou, Sotiris Bersimis, Christina Petrihou, Lefkothea Savva, Nicholas J. Legakis, Stylianos Chatzipanagiotou. **Is there a connection between inflammation, telomerase activity and the transcriptional status of telomerase reverse transcriptase in renal failure?** *Cellular and Molecular Biology Letters.* 2015 (20): 222-236